Loading...
NPI 1902376924 · Lakewood, CO · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Corporation Of America is a clinical medical laboratory provider located in Lakewood, Colorado. This profile covers 68 Medicare and 30 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Corporation Of America |
| Address | 7444 W Alaska Dr Ste 250 |
| City | Lakewood |
| State | CO |
| ZIP | 80226 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 3, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $11.7M |
| Medicare | $1.3M |
Laboratory Corporation of America in LAKEWOOD, CO operates as a high-volume clinical medical laboratory that mixes surgical pathology/cytopathology (codes such as 88305 and 88342) with large-scale molecular infectious and screening services (codes such as 87624, U0003, and 88175). The code mix — dominated by pathology interpretation and immunohistochemistry plus high-throughput nucleic acid testing — indicates an operation structured for centralized specimen processing and both professional and technical lab services.
Medicare revenue is heavily concentrated: the precomputed top 3 Medicare codes account for 68.9% of this provider's Medicare revenue, with 88305 alone representing $655.9K (51.7% of Medicare revenue) and ranking as an "extreme outlier, far above typical national volume for this code". That concentration around surgical pathology and related professional interpretation suggests the provider captures a disproportionate share of higher-value pathology billing within Medicare.
Medicaid revenue is also concentrated: the precomputed top 3 Medicaid codes account for 57.1% of Medicaid revenue, driven by U0003 ($3.3M, 28.3%), 87624 ($1.7M, 14.9%), and 88175 ($1.6M, 13.9%). U0003 is a statewide outlier, ranking #1 of 79 providers in-state (100th percentile, "extreme outlier, far above typical state volume for this code"), which points to dominant scale in COVID PCR/molecular testing for the Medicaid population.
This provider is effectively Medicaid-dominant on a revenue basis: total Medicaid revenue is $11.7M versus total Medicare revenue of $1.3M. That payer mix implies exposure concentrated to Medicaid reimbursement dynamics and state-level contracting, while Medicare represents a much smaller portion of overall billed revenue.
Competitive standing varies by payer and code: nationally the provider is an outlier on Medicare 88305 (rank #143 of 14580, 99th percentile) and is notably above typical on Medicare 88342 and 87624 (99th and 96th percentiles respectively), indicating strong national-level pathology volumes for select codes. At the state level the lab is a dominant/massive provider for molecular testing — U0003 rank #1 (100th percentile) and both 87624 and 88175 rank in the top three in-state (96th and 95th percentiles), reflecting market leadership in diagnostic PCR and HPV/cytology screening within the state.
Claim volumes support a high-throughput operation: Medicaid claim counts are very large for key codes (U0003 50.6K claims, 87624 55.8K claims, 88175 77.2K claims) and Medicare shows concentrated volume as well (88305 14.3K claims). These claim counts, together with the revenue distribution, are consistent with centralized specimen intake and automated testing workflows rather than low-volume, localized pathology services.
The provider’s NPI was enumerated on 2018-12-03 (~8 years ago), and the combination of relatively recent enumeration with the high current volumes suggests rapid scaling of laboratory throughput and payer contracting since enrollment. This tenure plus the observed code mix is consistent with an established, growth-oriented clinical lab network.
From a strategic and risk perspective, the provider relies on a small set of codes for the majority of revenue in both payers (top 3 Medicare codes = 68.9% and top 3 Medicaid codes = 57.1%), which concentrates financial exposure but also creates negotiating leverage for those service lines. The revenue base is diversified across pathology services and molecular infectious testing, which may partially mitigate payer-specific reimbursement swings even as dependence on a few high-volume codes remains a potential concentration risk.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
68 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 14,260 | $50 | $655.9K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 1,850 | $70 | $119.9K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 2,870 | $30 | $97.6K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 1,190 | $60 | $68.8K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under… | 2,540 | $30 | $65.9K |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 240 | $230 | $55.2K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 470 | $80 | $36.3K |
| 88112 | Selective cellular enhancement for cytopathology, such as the method of using a liquid–based slide preparation, uses a liquid–based medium to collect samples and preserve cells which can aid in… | 810 | $40 | $30.6K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 310 | $70 | $21.4K |
| 88304 | The physician, typically a pathologist, performs a level III examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 650 | $30 | $17.6K |
Showing 1–10 of 68
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
30 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 50,620 | $70 | $3.3M |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 55,780 | $30 | $1.7M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 77,180 | $20 | $1.6M |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 18,800 | $70 | $1.4M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 31,440 | $30 | $943.1K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 31,420 | $30 | $942.5K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 10,580 | $30 | $317.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 14,060 | $20 | $295.3K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 3,140 | $60 | $198.1K |
| 88141 | The physician analyzes and interprets a cervical or vaginal cytopathology specimen, using any reporting system, such as Bethesda or non–Bethesda. This code is for the professional interpretation by… | 8,100 | $20 | $121.5K |
Showing 1–10 of 30
How this provider's Medicaid billing volume and revenue compare to other Colorado providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Colorado median
30 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 13 | 40 | 110 | $160 | $326K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 80 | 830 | $70 | $274.8K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 2 | 20 | 590 | $30 | $230.4K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 2 | 20 | 910 | $20 | $206.3K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 10 | 130 | 670 | $50 | $192.3K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 4 | 60 | 360 | $30 | $183.5K |
| 87512 | The lab analyst performs a test to quantify infection with Gardnerella vaginalis using nucleic acid probe technique. Gardnerella vaginalis, typically causes bacterial vaginosis, an infection of the… | 3 | 10 | 2,270 | $50 | $159.7K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 4 | 70 | 350 | $30 | $150K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under… | 2 | 10 | 460 | $20 | $117.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 7 | 20 | 290 | $40 | $112.1K |
Showing 1–10 of 30
Other providers in the same ZIP code as Laboratory Corporation Of America, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.